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S U M M A R Y
Objectives: CC22-MRSA-IV, UK-EMRSA-15/Barnim EMRSA, is a common and pandemic strain of
methicillin-resistant Staphylococcus aureus (MRSA) that has been found mainly in Western Europe,
but also in other parts of the world including some Gulf countries. One suspected case of an infection
with this strain in a patient who was admitted to the surgical unit in Riyadh, Kingdom of Saudi Arabia
(KSA) was investigated in order to check whether this strain has reached KSA.
Methods: Besides the index isolate, 46 additional isolates of CC22-MRSA-IV from patients from KSA, Abu
Dhabi, Kuwait, and Germany (patients with a history of travel in the Middle East), were characterized by
microarray hybridization.
Results: The study revealed a regional presence of as many as six distinct ‘strains’ of CC22-MRSA-IV that
could be distinguished based on carriage of SCCmec IV subtypes and virulence factors. No true UK-
EMRSA-15/Barnim EMRSA was identiﬁed in Riyadh; all suspected isolates from Riyadh were assigned to
other, albeit related strains. However, this strain was identiﬁed in Abu Dhabi and Kuwait.
Conclusions: CC22-MRSA-IV from KSA could be linked to other epidemic strains from the Middle East
and possibly India, rather than to the Western European UK-EMRSA-15/Barnim EMRSA. High-resolution
typing methods, including SCCmec subtyping, might help to differentiate related epidemic strains and to
monitor routes of transmission.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Epidemic methicillin-resistant Staphylococcus aureus (EMRSA)-
15 (CC22-MRSA-IV) was ﬁrst identiﬁed in the UK in the early 1990s
and has become the most prevalent hospital-acquired strain of
methicillin-resistant Staphylococcus aureus (MRSA) in the UK.1,2* Corresponding author.
E-mail address: monecke@rocketmail.com (S. Monecke).
http://dx.doi.org/10.1016/j.ijid.2016.08.016
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).This pandemic MRSA strain has also been reported from many
other regions of the world, including Ireland, Germany (where it is
called ‘Barnim EMRSA’ after the county in which it was ﬁrst found),
Denmark, Belgium, Spain, Portugal, Malta, Sweden, Singapore,
Australia, New Zealand, Qatar, and Kuwait.1,3–21 CC22-MRSA-IV
that differ in harbouring tst1 (encoding toxic shock toxin) have
been reported from the Gaza Strip, Jordan, the United Arab
Emirates (UAE), the Kingdom of Saudi Arabia (KSA), Kuwait, the
USA, and Italy.11,20,22–26 Furthermore, CC22-MRSA-IV harbouring
the genes encoding the Panton–Valentine leukocidin (PVL) haveciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
A. Senok et al. / International Journal of Infectious Diseases 51 (2016) 31–3532frequently been observed in the Middle East,5,11,27 Iran,28 and
India,29–31 and also in sporadic cases32 and localized outbreaks33 in
other regions, such as Western Europe.
In this report, the characteristics of CC22-MRSA-IV causing an
infection in a patient who presented to the surgical unit of King
Khalid University Hospital (KKUH) in Riyadh, KSA, are presented.
Furthermore, the molecular typing of CC22-MRSA-IV isolated in
the Arabian Gulf region and from patients from Germany with a
history of previous travel to the Middle East is discussed.
2. Materials and methods
2.1. Case history
A middle-aged male patient presented to the surgical unit of
KKUH with a history of intermittent fever and peri-umbilical pain,
with an associated peri-umbilical discharge of 2-week duration.
The patient gave a history of travel to Egypt (including healthcare
exposure) and of two previous surgical interventions at different
hospitals during the last few years. The ﬁrst one was a gastric by-
pass procedure; the second one an abdominal herniorrhaphy with
mesh implant. He received antibiotics, but neither details of the
antibiotic therapy nor information on the laboratory investigations
were available. There was no history of any chronic illness apart
from the presenting complaints. No family members were
documented to have recurrent skin or soft tissue infections.
On admission, the patient had stable vital signs. Physical
examination revealed an anterior abdominal wall scar running
from the xiphoid process to the umbilicus and a discharging wound
in the umbilical area. There was associated tenderness in the para-
umbilical and left hypogastric areas. Investigations carried out at
presentation included an abdominal computed tomography scan,
which was signiﬁcant for thickening of the anterior abdominal wall
with minimal subcutaneous collection. A culture of the wound
swab collected at presentation yielded a mixed growth of Klebsiella
pneumoniae, which was sensitive to all tested antibiotics, and
MRSA, which was resistant to penicillin, ampicillin, and imipenem
but susceptible to gentamicin, ciproﬂoxacin, erythromycin, rifam-
picin, trimethoprim/sulfamethoxazole, tetracycline, and vancomy-
cin. The patient underwent wound debridement with partial mesh
removal and drainage a day after presentation, and the postopera-
tive period was uneventful. He was discharged 3 days after
presentation on a combination of clindamycin (450 mg, 8-hourly)
and ciproﬂoxacin (750 mg, 12-hourly). At the 2-week follow-up
visit, the patient’s wound had healed completely.
2.2. Additional isolates
Additional isolates were included for comparison. All had
previously been identiﬁed as CC22-MRSA-IV using the StaphyType
DNA microarray (see below). These included isolates with
hybridization proﬁles consistent with UK-EMRSA-15/Barnim
EMRSA, as well as some randomly selected PVL- or tst1-positive
CC22-MRSA-IV strains. These isolates originated from Riyadh
(KSA; ﬁve isolates sampled in 2014 and 13 sampled in 2010/11),
Abu Dhabi (UAE; n = 16 sampled in 2009/10), and Kuwait (n = 6;
2013), as well as from Germany. The German isolates included
some local UK-EMRSA-15/Barnim EMRSA isolates (n = 4; 2015/16)
and some PVL- or tst1-positive CC22-MRSA-IV from patients with a
history of recent travel in the Middle East (n = 3; 2014–2016).
2.3. Array procedures
Molecular characterization of the MRSA isolate from the index
case was performed as part of a wider study in which archived
MRSA isolates from KKUH were characterized using the StaphyTypeDNA microarray (Alere Technologies GmbH, Jena, Germany).
Probes, primers, and procedures have been described previously
in detail,11,34 and protocols are provided by the manufacturer.
Additional probes and primers were used in order to discern
SCCmec subtypes and CC22 strains (Table 1). Ampliﬁcation and
hybridization protocols were identical to those described previ-
ously.11,34
3. Results
The recovered isolate harboured the accessory gene regulator
(agrI) and capsular genes type 5 (cap5), as well as genes for collagen
adhesin (cna), Staphylococcus aureus surface protein G (sasG), and
the egc cluster. This was in accordance with previously character-
ized CC22 isolates and strains.11,34 Furthermore, it harboured mecA
as part of an SCCmec IV element. It lacked the genes encoding
ﬁbronectin-binding protein B (fnbB), exfoliative toxin (etA, etB, and
etD), toxic shock toxin (tst), and PVL, as well as the arginine
catabolic mobile element (ACME). Based on this proﬁle, the isolate
was preliminarily regarded as CC22-MRSA-IV, UK-EMRSA-15/
Barnim EMRSA. Staphylokinase (sak), chemotaxis-inhibiting pro-
tein (chp), and Staphylococcus complement inhibitor (scn) genes
were present, and enterotoxin C and L genes (sec and sel) were
absent.
SCCmec subtyping using new probes revealed that this isolate
differed in SCCmec subtype from Western European UK-EMRSA-
15/Barnim EMRSA isolates (that harbour SCCmec IV h/j) in the
carriage of an SCCmec element of subtype IVa. The hybridization
pattern of the actual isolate (Table 2) matched the computed/
predicted pattern for the sequence of strain CMFT503, GenBank
HF569113.1, yielding signals for mecA, ugpQ, delta mecR1, mvaS,
cstB-SCC2, Q93IB7, ccrA/B-2, and ‘SCCterm 1’ (an intergenic region
between orfX and the ﬁrst codons of the SCC element that is
alternative to dcs).
Based on this observation, a convenience sample of 46 addi-
tional isolates was selected and subtyped for comparison (see
Materials and methods). When focusing on SCCmec IV subtypes as
well as on the carriage of PVL and tst1 genes, these 46 isolates could
be categorized into six distinct variants, or strains. Details are
shown in Table 2. All Saudi isolates differed from the Western
European UK-EMRSA-15/Barnim EMRSA CC22-MRSA-IV h/j. How-
ever, this strain was identiﬁed in Abu Dhabi (UAE) and Kuwait.
4. Discussion
The changing epidemiology of MRSA necessitates the continu-
ous surveillance of patients. Well-documented hospital and
community strains of MRSA in Saudi Arabia include ST239-
MRSA-III, ST80-MRSA-IVc, and ST30-MRSA-IV.27
In this report, the characteristics of a CC22-MRSA-IV (CC22-IV)
isolate from a patient in Saudi Arabia are presented; this isolate
was similar but not identical to the widely distributed UK-EMRSA-
15/Barnim EMRSA. On investigating this case and other similar
isolates from KSA and other regions, several different strains (or
very distinct variants) of CC22-IV could be distinguished based on
SCCmec IV subtypes and the carriage of clinically important toxin
genes.
These included UK-EMRSA-15/Barnim EMRSA as described
from Western Europe (see Introduction). These isolates have
SCCmec IV h/j elements and do not carry tst1 or PVL genes, but
frequently harbour enterotoxin C and L genes (sec and sel). Usually
they are phenotypically resistant to ciproﬂoxacin, often also to
erythromycin and clindamycin (mediated by erm(C)). Other
resistance properties, however, are rather rare. This strain is also
susceptible to weak lysis by phage 75.1
Table 1
Markers used for subtyping of CC22-MRSA-IV
Gene Gene product/function Probe(s) Primer(s)
agr groups I–IV,
capsule type 5 and 8
agr- and capsule-speciﬁc probes (agr I and capsule
type 8 alleles present in CC22)
11,34 11,34
mecA Modiﬁed penicillin binding protein (PBP2a) causing
oxacillin/methicillin resistance and thus deﬁning
MRSA
11,34 11,34
ccrA/B-2 Cassette chromosome recombinase A allele found in
SCCmec II and IV elements
11,34 11,34
mvaS-SCC Truncated 3-hydroxy-3-methylglutaryl CoA
synthase, variably present in SCCmec I, II, IV, V
BA000033.2 [37280:37304] and
BA000033.2 [37432:37460]
BA000033.2 [37307:37326:r]
and BA000033.2
[37488:37510:r]
cstB-scc2 (IVa) CsoR-like sulfur transferase-regulated genes B/
metallo-beta-lactamase superfamily protein
(truncated); present in SCCmec X, variably present in
SCCmec I and IV; marker for IVa
CP000046.1 [54284:54313:r]
and CP000046.1
[53882:53910:r]
CP000029.1
[2492569:2492590:r] and
CP000046.1 [53836:53854]
B2Y834 Abortive phage resistance protein used for
identiﬁcation of SCCmec IV A, G, c and SCCmec
MRSAZH47
AE015929.1 [51095:51119] AE015929.1 [51124:51144:r]
B6VQU0 Putative protein used for identiﬁcation of SCCmec
IVh/j
AB425824.1 [20412:20443] AB425824.1 [20498:20525:r]
Q93IB71 LytTR domain DNA-binding regulator present in
some SCCmec III elements and in IVa from CMFT503
GenBank HF569113.1
FN433596.1 [434532:434550] FN433596.1 [68041:68058]
Q9XB68-dcs Located at the terminus of SCCmec directly next to
orfX, comprises the downstream constant segment
(dcs) that includes a copy of the SCC direct repeat
DR_SCC (AGAAGCTTATCATAAGTAA)
11,34 11,34
SCCmec Terminus 1 SCC integration site alternate to dcs GU235983.1 [568:594] FN433596.1 [67354:67380:r]
SCCmec Terminus 5 SCC integration site alternate to dcs AB425427.1 [754:779] AB425427.1 [800:824:r]
erm(C) rRNA adenine N-6-methyltransferase
macrolide–lincosamide–streptogramin B resistance
protein
11,34 11,34
aacA-aphD Bifunctional enzyme Aac/Aph, 60-aminoglycoside N-
acetyltransferase/20 0-aminoglycoside
phosphotransferase; gentamicin and tobramycin
resistance
11,34 11,34
aadD Aminoglycoside adenyltransferase, tobramycin
resistance
11,34 11,34
dfrA Dihydrofolate reductase, mediates trimethoprim
resistance
11,34 11,34
lukF/S-PV Panton–Valentine leukocidin 11,34 11,34
tst1 Toxic shock syndrome toxin 11,34 11,34
sec+sel Enterotoxins C and L 11,34 11,34
egc cluster Enterotoxin gene cluster (comprising seg, sei sem, sen,
seo, seu)
11,34 11,34
sak, chp, scn Staphylokinase, chemotaxis-inhibiting protein,
staphyl. complement inhibitor
11,34 11,34
eta, etb, etd Exfoliative toxins 11,34 11,34
ACME Arginine catabolic mobile element 11,34 11,34
fnbB Fibronectin binding protein B, variably detected in
CC22 because it is in some strains fused with fnbA
11,34 11,34
cna, sasG Collagen adhesin; Staphylococcus aureus surface
protein G (present in CC22)
11,34 11,34
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18 KSA isolates characterized herein could be assigned to UK-
EMRSA-15/Barnim EMRSA, mainly because of the carriage of other
SCCmec IV subtypes. Some isolates from Kuwait and Abu Dhabi
matched this strain. Furthermore, two additional isolates from Abu
Dhabi had an SCCmec IV variant element that has apparently not
yet been described or sequenced.
Another related epidemic strain – ST22-MRSA-IVa – is usually
reported to carry tst1 as well as SCCmec IVa. It is probably widely
distributed in the Middle East and the Mediterranean, and is
sometimes dubbed the ‘Gaza epidemic strain’.11,20,22–25,27 Study
isolates that could be assigned to this strain originated from KSA,
Abu Dhabi, and Kuwait, or were isolated in Germany from patients
with a history of travel to the Middle East.
There were also tst1-negative isolates with SCCmec IVa
elements. Previously observed UK-EMRSA-15/Barnim EMRSA-like
isolates from KSA have belonged to this category,27 as well as theisolate from the case described herein. It can be assumed that they
might rather be tst1 deletion mutants of the Middle Eastern ‘Gaza
epidemic strain’ than derived from imported European UK-
EMRSA-15/Barnim EMRSA.
Furthermore, three tst1-negative isolates (one each from KSA,
Abu Dhabi, and Kuwait) were found to carry SCCmec IV b/d/i
elements.
Finally, there were a number of PVL-positive CC22-IV. All
characterized isolates of PVL-positive CC22-MRSA-IV had SCCmec
IVc elements, ruling out the possibility that they directly evolved
from UK-EMRSA-15/Barnim EMRSA by acquisition of a PVL phage.
This strain also appears to be present in India (with two recent
genome sequences being virtually identical to the isolates tested
herein: http://www.ncbi.nlm.nih.gov/bioproject/PRJDB1743 and
http://www.ncbi.nlm.nih.gov/bioproject/PRJDB2070). This sug-
gests an epidemiological link to the Arabian Gulf, as previously
also assumed for other MRSA.35
Table 2
CC22-MRSA-IV strains and isolates
Isolates CC22-MRSA-IV
with SCCmec IVa
UK-EMRSA-15/Barnim
EMRSA with SCCmec
IV h/j
CC22-MRSA-IV
with unknown
SCCmec IV h/j
variant
tst1-positive ‘Gaza epidemic
strain’ with SCCmec IVa
CC22-MRSA-IV with
SCCmec IV b/d/i
PVL-positive
CC22-MRSA-IV
with SCCmec IVc
Index case from
the case report
and 3 others
from Riyadh
(2010/11)
7 isolates from
Abu Dhabi (2009/10),
2 from Kuwait (2013),
and, for comparison,
4 from Dresden
(locals; 2015/16)
2 from
Abu Dhabi
(2009/10)
2 isolates from Abu Dhabi
(2009/10), 2 from Kuwait
(2013), 2 from Riyadh
(2014), 4 from Riyadh
(2010/11), 2 from Dresden
(with travel history; 2016)
1 from Riyadh (2014),
1 from Abu Dhabi
(2009/10), 1 from
Kuwait (2013)
4 from Abu Dhabi
(2009/10),
1 from Kuwait
(2013), 1 from
Riyadh (2014),
6 from Riyadh
(2010/11),
1 from Dresden
(with travel
history; 2014)
mecA Positive Positive Positive Positive Positive Positive
ccrA/B-2 Positive Positive Positive Positive Positive Positive
mvaS-SCC Positive Positive Positive Positive Positive Negative
cstB-scc2 (IVa) Positive Negative Positive Positive Negative Negative
B2Y834 (IVc) Negative Negative Negative Negative Negative Positive
B6VQU0 (IV h/,j) Negative Positive Positive Negative Negative Negative
Q93IB71 Positive Negative Negative Positive Negative Negative
Q9XB68-dcs Negative Positive Negative Negative Positive Positive
SCCmec Terminus 1 Positive Negative Negative Positive Negative Negative
SCCmec Terminus 5 Negative Negative Positive Negative Negative Negative
erm(C) Negative Variable Negative Variable Variable Variable
aacA-aphD Negative Negative Negative Negative Negative Positive
aadD Negative Negative Negative Negative Negative Variable
dfrA Negative Negative Negative Negative Negative Variable
lukF/S-PV Negative Negative Negative Negative Negative Positive
tst1 Negative Negative Negative Positive Negative Negative
sec+sel Negative Variable Negative Negative Positive Negative
egc cluster Positive Positive Positive Positive Positive Positive
fnbB Negative Negative Negative Negative Variable Variable
A. Senok et al. / International Journal of Infectious Diseases 51 (2016) 31–3534In conclusion, ‘true’ UK-EMRSA-15/Barnim EMRSA was not
identiﬁed from KSA, with all tested CC22-MRSA-IV differing either
in toxin carriage and/or in SCCmec subtype. UK-EMRSA-15/
Barnim-like strains from KSA might have evolved independently
from other Middle Eastern CC22-MRSA-IV (by loss of tst1) or
directly from methicillin-sensitive S. aureus, by acquisition of
SCCmec IV b/d/i.
Due to the small number of isolates characterized herein, it is
not possible to state that UK-EMRSA-15/Barnim EMRSA does not
exist in KSA at all, or whether it is just less common than the other
CC22-MRSA-IV strains.
UK-EMRSA-15/Barnim EMRSA was found in other countries in
the region. The higher prevalence of this strain in Kuwait and the
UAE than in KSA could possibly be attributed to the higher number
of European expatriates and tourists in Kuwait and the UAE.
One might also wonder what makes CC22-MRSA-IV so
successful an entity that at least six different CC22-MRSA-IV
strains co-exist in the Arabian Gulf region.
The isolation and characterization of these isolates underscores
the diversity of CC22 MRSA strains based on SCCmec subtyping, as
well as the potential of SCCmec subtyping for molecular
epidemiology. It also calls for continued surveillance and
screening, including the application of highly sensitive molecular
methods for the characterization of isolates.
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